Archer 1042: A Phase 2 Study Of Dacomitinib In Advanced Non-Small Cell Lung Cancer (Post-Chemotherapy Or Select First Line Patients) To Evaluate Prophylactic Intervention On Dermatologic And Gastrointestinal Adverse Events And Patient Reported Outcomes

Trial Profile

Archer 1042: A Phase 2 Study Of Dacomitinib In Advanced Non-Small Cell Lung Cancer (Post-Chemotherapy Or Select First Line Patients) To Evaluate Prophylactic Intervention On Dermatologic And Gastrointestinal Adverse Events And Patient Reported Outcomes

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Dacomitinib (Primary) ; Alclometasone; Doxycycline; Probiotics
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms ARCHER-1042
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jun 2016 Results published in the Annals of Oncology
    • 22 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 02 Jun 2015 Results on dermatological adverse events from cohorts I and II presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top